The reality of continuous pharmaceutical manufacturing

Taking place on 26th to 28th March 2019 at the National Formulation Centre in Sedgefield, the conference will cover a number of topics around CM technologies, which are predicted to help meet the UK pharmaceutical industry’s demand for faster product development, reduced costs and increased manufacturing flexibility.

The event will include a series of presentations from early adopters of continuous manufacturing strategies, in particular examining the development and manufacture of oral solid dosage (OSD). The speaking panel will include AstraZeneca, Bayer, CMAC, GSK, Janssen, Merck, UCB Pharma and the University of Sheffield.

Now gaining momentum across the UK pharmaceutical manufacturing sector, continuous manufacturing presents a new approach to OSD production, allowing businesses to benefit from higher production yields, lower utility consumption and reduced waste.

Continuous Manufacturing is helping companies move away from time-consuming batch processing and is a key enabler of building quality by design into the complete product lifecycle from research and development through to manufacturing.

Jan Verelst, Siemens’ Global Business Development Manager for SIPAT & Continuous Manufacturing, said: “By listening to user experiences, attendees will be able to hear more about how CM is assisting the industry produce higher quality products, enhance drug safety and reduce its industrial footprint for a sustainable future.”